esperion - Synonyms for esperion | Synonyms Of esperion

Examples of "esperion"
Pfizer acquired the original Esperion in 2004 for as a defensive move to prevent ETC-216 from falling into competitors' hands. Two years later, in 2006, Pfizer decided to kill the Esperion organization and development of ETC-216. In May 2008, Dr. Roger Newton, Esperion's founder and chief scientific officer, who co-discovered the statin marketed as Lipitor® — the most commonly prescribed LDL-C lowering therapy in the world and best-selling drug in the pharmaceutical industry’s history, raised sufficient capital to acquire rights to ETC-1002 and Esperion from Pfizer, thereby leading to a second independent period for the company. In June 2013, Esperion became a public company again through an initial public offering. , Esperion was traded on NASDAQ under the symbol "ESPR".
To date, Esperion has studied ETC-1002 in ten completed clinical trials and treated approximately 726 patients with ETC-1002 across completed Phase 1 and 2 studies.
Hoping to develop a more effective treatment than their current product Lipitor, Pfizer purchased and internalized Esperion shortly before JAMA published the results of the Apo A-1 Milano trial.
Esperion, divested by Pfizer in 2008, is back in business and continue to work on HDL mimetic therapies. The company established an agreement with TransGenRx as a protein source.
In 2003, the company acquired Esperion Therapeutics for $1.3 billion (later selling the unit in 2008), protecting Lipitor from ETC-216. In 2004, Pfizer announced it would acquire Meridica for $125 million. In 2005, the company made a number of acquisitions: Vicuron Pharmaceuticals for $1.9 billion, Idun for just less than $300 million and finally Angiosyn for $527 million.
Esperion Therapeutics, Inc. is a public, American pharmaceutical company focused on the development of a first-in-class, orally available, small molecule designed to significantly lower elevated levels of LDL-C - with the reduced potential for muscle-related side effects associated with statin use. The company is headquartered in Ann Arbor, Michigan.
The ApoA-1 Milano Trial, published in JAMA in 2003, was the first published placebo controlled, 2 dose level, trial in humans. This was a secondary prevention trial in that those included were individuals who presented to a participating hospital with unstable angina and agreed to consent to a rigorous trial, well beyond usual clinical practice testing and treatment, testing whether this HDL protein variant, which was so effective in animals, would also work in humans. This trial was initiated by Steven Nissen of the Cleveland Clinic after prompting by Roger Newton of Esperion to examine the effects of the mutant protein using intravascular ultrasound imaging. Esperion provided the protein, code named ETC-216, for the duration of the trial.
In 2003 Nissen led a "Journal of the American Medical Association" study, producing evidence that five weekly infusions of ApoA-I Milano/phospholipids complex, a synthetic form of HDL, can possibly remove significant amounts of plaque from coronary arteries. The lipoprotein enhanced the ability of HDL, or “good” cholesterol to usher fat out of the arteries and into the liver for excretion leading to the purchase of Esperion Therapeutics, the tiny company that had produced recombinant Apo-A1 Milano, by Pfizer for $1.3 billion.
Esperion Therapeutics, a high tech venture capital start-up, demonstrated proof of efficacy in both animals and humans, spending many millions of dollars over several years to conduct a single human trial which showed impressive and rapid efficacy by IVUS of coronary arteries. However, over the course of the project they produced only enough ApoA-1 Milano to partially treat thirty out of the forty-five people in the randomized trial, giving them one weekly dose each for five weeks. The results of the trial were published in JAMA (November 5, 2003).